In another study using CRISPR/Cas9 genomic editing of the BCR-ABL fusion gene, García-Tuñón and his group were the first to report the use of CRISPR/Cas9 genome editing to abrogate the human BCR-ABL oncoprotein in leukemia cells as a therapeutic intervention [33]. This evidence concerns the gene ABL1 and leukemia.